ICP-189 is under clinical development by InnoCare Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ICP-189’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ICP-189 overview

ICP-189 is under development for the treatment of solid tumors, lung cancer , non-small cell lung cancer and cervical cancer. It is administered through oral route. It acts by targeting tyrosine protein phosphatase non receptor type 11.

InnoCare Pharma overview

InnoCare Pharma (InnoCare) is a biopharmaceutical company that discovers and develops novel treatments for cancer and autoimmune diseases. The company’s pipeline product portfolio includes ICP-022 a Bruton Tyrosine Kinase (BTK) inhibitor to treat B cell malignancies; ICP-105, an inhibitor for the treatment of hepatocellular carcinoma (HCC); ICP-192 a novel compound that targets gene abnormalities in solid tumor. It serves in the therapeutic areas of gastrointestinal cancer, liver cancer, lupus and rheumatoid arthritis. The company builds a fully integrated biopharmaceutical platform with strong in-house research and development capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control. It operates in the US and China. InnoCare is headquartered in Changping, Beijing, China.

For a complete picture of ICP-189’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.